Financial Advisory Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Financial Advisory Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,125	Closed	-$290K	–	71
2024 Q2	$290K	Hold	3,125	–	–	0.11%	61
2024 Q1	$297K	Hold	3,125	–	–	0.11%	59
2023 Q4	$279K	Hold	3,125	–	–	0.1%	60
2023 Q3	$228K	Hold	3,125	–	–	0.09%	63
2023 Q2	$260K	Hold	3,125	–	–	0.1%	61
2023 Q1	$238K	Hold	3,125	–	–	0.09%	63
2022 Q4	$259K	Hold	3,125	–	–	0.11%	63
2022 Q3	$248K	Hold	3,125	–	–	0.11%	62
2022 Q2	$232K	Hold	3,125	–	–	0.1%	64
2022 Q1	$281K	Hold	3,125	–	–	0.1%	64
2021 Q4	$350K	Buy	+3,125	New	+$377K	0.13%	64

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Financial Advisory Partners's XBI Position: Q3 2024 in Review

Financial Advisory Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 3,125 shares — an estimated $290K sold.

Financial Advisory Partners first reported a position in XBI in Q4 2021 and held it in 11 quarters. The position peaked at $350K in Q4 2021. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Financial Advisory Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
Financial Advisory Partners sold 3,125 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $290K.
Financial Advisory Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 11 quarters.
Financial Advisory Partners's State Street SPDR S&P Biotech ETF position peaked at $350K in Q4 2021.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Financial Advisory Partners's 13F filing for Q3 2024, filed 9 Oct 2024.